<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>The report identifies promising market opportunities in developing novel therapies for dementia associated with Alzheimer's disease. Over 80 companies with 100+ pipeline drugs focus on innovative approaches, such as genetically targeted treatments and enhanced drug delivery systems, particularly in mid to late-stage clinical trials.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/4330698/dementia-associated-with-alzheimers-disease?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=n5kmfw&amp;utm_campaign=2253238+-+Dementia+Associated+With+Alzheimer%27s+Disease+Market+Research+Report+2026%3a+Overview+of+Over+80+Companies+and+More+Than+100+Pipeline+Drugs&amp;utm_exec=chdomsai" rel="nofollow" target="_blank" title="Dementia Associated With Alzheimer'S Disease - Pipeline Insight, 2026">"Dementia Associated With Alzheimer'S Disease - Pipeline Insight, 2026"</a> has been added to ResearchAndMarkets.com's offering. The report provides a detailed overview of over 80 companies and more than 100 pipeline drugs targeting Dementia Associated With Alzheimer's Disease. This comprehensive analysis includes drug profiles at various stages, from clinical to nonclinical, and evaluates therapeutics based on product type, development stage, administration route, and molecule type. Additionally, the report highlights inactive products within the landscape. Global Coverage Dementia, predominantly caused by Alzheimer's Disease (AD), manifests as a significant cognitive decline, leading to challenges in daily living activities. Characterized by amyloid-beta plaques and tau protein tangles, AD is genetically linked, especially involving mutations in APP, PSEN1, and PSEN2 genes. The genetic APOE ?4 allele is particularly associated with late-onset AD. Diagnosis of AD-associated dementia involves comprehensive evaluations, including cognitive testing, neurological exams, and advanced imaging techniques to identify brain alterations. Despite the lack of a definitive cure, symptomatic treatments are available, primarily involving cholinesterase inhibitors and NMDA antagonists. The report gives an expansive insight into the current scenario, including commercial assessments and detailed clinical evaluations of development-stage drugs. It discusses drug mechanisms, clinical studies, NDA approvals, technology platforms, collaborations, and market activities. Key Highlights The research outlines the strategic initiatives of companies aiming to address R&amp;D challenges in Dementia Associated With Alzheimer's Disease through novel therapies. Drug development phases detail insights into specific stages like Phase II and III, highlighting pharmacological actions, collaborations, and recent breakthroughs. Therapeutic Assessment and Development Activities The report categorizes drugs by factors like development phase, route of administration (including intra-articular, intravenous, oral routes), and molecule types such as oligonucleotides and small molecules. It highlights ongoing therapeutic development, industry partnerships, mergers, acquisitions, and significant milestones. Emerging Drug Candidates <ul><li>Trontinemab - F. Hoffmann-La Roche Ltd.: An innovative amyloid-beta antibody engineered for improved brain access, currently in Phase III trials.</li><li>E2814 - Eisai Co., Ltd.: A targeted anti-MTBR tau antibody aiming to disrupt tau pathology, under Phase II/III evaluation.</li><li>MK-1167 - Merck &amp; Co. / Neuphoria Therapeutics, Inc.: A cognitive enhancement drug, targeting nicotinic acetylcholine receptors, in Phase II trials.</li><li>ONO-2020 - ONO PHARMACEUTICAL CO., LTD.: An epigenetic modulator influencing gene expression, currently in Phase II trials.</li><li>ARO-MAPT - Arrowhead Pharmaceuticals, Inc.: A tau protein synthesis inhibitor, evaluated at Phase I/II development.</li><li>COYA 302 - Coya Therapeutics, Inc./Dr. Reddy's Laboratories Ltd.: A biologic with dual immunomodulatory action, preclinically evaluated for its potential to treat AD.</li></ul> Report Insights <ul><li>Dementia Associated With Alzheimer's Disease Pipeline Analysis</li><li>Therapeutic Assessment</li><li>Unmet Needs and Market Impact</li></ul> Key Questions Addressed <ul><li>Current development landscape and company efforts</li><li>Mid-stage and late-stage emerging therapies</li><li>Industry collaborations and licensing activities</li><li>Novel technological advancements and trends</li><li>Status of ongoing clinical studies</li></ul> Key Industry Players <ul><li>F. Hoffmann-La Roche Ltd.</li><li>Eisai Co., Ltd.</li><li>Merck &amp; Co. / Neuphoria Therapeutics, Inc.</li><li>ONO PHARMACEUTICAL CO., LTD.</li><li>Arrowhead Pharmaceuticals, Inc.</li><li>Coya Therapeutics, Inc./Dr. Reddy's Laboratories Ltd.</li></ul> Key Topics Covered: Introduction Executive Summary Dementia Associated With Alzheimer's Disease: Overview <ul><li>Introduction</li><li>Causes</li><li>Diagnosis</li><li>Treatment</li></ul> Pipeline Therapeutics <ul><li>Comparative Analysis</li></ul> Therapeutic Assessment <ul><li>Assessment by Product Type</li><li>Assessment by Stage and Product Type</li><li>Assessment by Route of Administration</li><li>Assessment by Stage and Route of Administration</li><li>Assessment by Molecule Type</li><li>Assessment by Stage and Molecule Type</li></ul> Dementia Associated With Alzheimer's Disease- Analytical Perspective Late Stage Products (Phase III) <ul><li>Comparative Analysis</li></ul> Trontinemab: F. Hoffmann-La Roche Ltd. <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Mid Stage Products (Phase II) <ul><li>Comparative Analysis</li></ul> MK-1167: Merck &amp; Co. / Neuphoria Therapeutics, Inc. <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Early Stage Products (Phase I/II) <ul><li>Comparative Analysis</li></ul> ARO-MAPT: Arrowhead Pharmaceuticals, Inc. <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Preclinical and Discovery Stage Products <ul><li>Comparative Analysis</li></ul> COYA 302: Coya Therapeutics, Inc/Dr. Reddy's Laboratories Ltd. <ul><li>Product Description</li><li>Research and Development</li><li>Product Development Activities</li></ul> Inactive Products <ul><li>Comparative Analysis</li></ul> Dementia Associated With Alzheimer's Disease Key Companies Dementia Associated With Alzheimer's Disease Key Products Dementia Associated With Alzheimer's Disease - Unmet Needs Dementia Associated With Alzheimer's Disease - Market Drivers and Barriers Dementia Associated With Alzheimer's Disease - Future Perspectives and Conclusion Dementia Associated With Alzheimer's Disease Analyst Views Dementia Associated With Alzheimer's Disease Key Companies Appendix For more information about this clinical trials report visit <a href="https://www.researchandmarkets.com/reports/4330698/dementia-associated-with-alzheimers-disease?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=n5kmfw&amp;utm_campaign=2253238+-+Dementia+Associated+With+Alzheimer%27s+Disease+Market+Research+Report+2026%3a+Overview+of+Over+80+Companies+and+More+Than+100+Pipeline+Drugs&amp;utm_exec=chdomsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/wmfcfu</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MDZiZWE1N2EtNGQ3Ni00MjZmLTk2MjQtZGQ5Y2RmZmRlODk3LTEwMjY3MzctMjAyNi0wNS0xNS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Dementia Associated With Alzheimer's Disease Market Research Report 2026: Overview of Over 80 Companies and More Than 100 Pipeline Drugs

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn